Statin labeling should be revised with updated warnings, meta-analysis confirms
Statins are commonly prescribed to help patients lower their LDL cholesterol levels and minimize their risk of cardiovascular disease. The labeling for these popular drugs currently warns of an increased risk of cognitive impairment, depression, sleep disturbance, erectile dysfunction, peripheral neuropathy and dozens of other complications.
However, according to a new meta-analysis published in The Lancet, there is no evidence that statin therapy actually causes a majority of those issues.
“Statin therapy has been used by hundreds of millions of people worldwide over the past 30 years, and the data show that statin use has contributed substantively to age-specific reductions in global cardiovascular disease mortality and morbidity,” wrote first author Christina Reith BSc, MBChB, PhD, a researcher with the University of Oxford, and the rest of the Cholesterol Treatment Trialists’ Collaboration writing committee. “However, concerns about the safety of statins have been raised, with claims of excesses in a wide range of conditions in multiple organ systems.”
The group evaluated data from more than 123,000 patients who originally participated in one of 19 trials comparing statin therapy with a placebo. Statins evaluated in these trials included atorvastatin, fluvastatin, pravastatin, rosuvastatin and simvastatin. The mean age was 63 years old and median follow-up period was 4.5 years.
Overall, the group did confirm that statin therapy was associated with an increased risk of abnormal liver transaminases and other liver function abnormalities, urinary composition alterations and edema. Otherwise, however, there was no evidence that statin therapy caused the other 62 potential side effects currently printed on statin labels.
“These findings reinforce previous conclusions that any risks associated with statin therapy are greatly outweighed by their cardiovascular benefits,” the authors wrote. “Consequently, there is a pressing need for regulatory authorities to require revision of statin labels and for other official sources of health information to be updated, so that clinicians, patients, and the public can make informed decisions regarding the balance of the benefits and risks of statin therapy.”
Click here for the full analysis.
Michael has more than 19 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.